These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1401056)

  • 21. Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation.
    Grompe M; al-Dhalimy M
    Hum Mutat; 1995; 5(1):105. PubMed ID: 7728147
    [No Abstract]   [Full Text] [Related]  

  • 22. Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.
    Rootwelt H; Chou J; Gahl WA; Berger R; Coşkun T; Brodtkorb E; Kvittingen EA
    Hum Genet; 1994 Jun; 93(6):615-9. PubMed ID: 8005583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
    Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
    J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoplasmic nonsense-mediated mRNA decay for a nonsense (W262X) transcript of the gene responsible for hereditary tyrosinemia, fumarylacetoacetate hydrolase.
    Dreumont N; Maresca A; Khandjian EW; Baklouti F; Tanguay RM
    Biochem Biophys Res Commun; 2004 Nov; 324(1):186-92. PubMed ID: 15465000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.
    Phaneuf D; Labelle Y; Bérubé D; Arden K; Cavenee W; Gagné R; Tanguay RM
    Am J Hum Genet; 1991 Mar; 48(3):525-35. PubMed ID: 1998338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine and its catabolites: from disease to cancer.
    Tanguay RM; Jorquera R; Poudrier J; St-Louis M
    Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
    Phaneuf D; Hadchouel M; Tanguay RM; Bréchot C; Ferry N
    Biochem Biophys Res Commun; 1995 Mar; 208(3):957-63. PubMed ID: 7702626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1.
    Bergeron A; D'Astous M; Timm DE; Tanguay RM
    J Biol Chem; 2001 May; 276(18):15225-31. PubMed ID: 11278491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
    Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
    Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
    Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD
    Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fumarylacetoacetase mutations in tyrosinaemia type I.
    Rootwelt H; Høie K; Berger R; Kvittingen EA
    Hum Mutat; 1996; 7(3):239-43. PubMed ID: 8829657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel homozygous mutation causing hereditary tyrosinemia type I in yakut patient in russia: case report.
    Maksimova NR; Gurinova EE; Sukhomyasova AL; Danilova AL; Kaimonov VS; Savvina MT; Yakovleva AE; Alekseeva EI
    Wiad Lek; 2016; 69(2 Pt 2):295-8. PubMed ID: 27487552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
    Morrow G; Angileri F; Tanguay RM
    Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.
    Rootwelt H; Brodtkorb E; Kvittingen EA
    Am J Hum Genet; 1994 Dec; 55(6):1122-7. PubMed ID: 7977370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
    Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
    Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
    Nicole LM; Valet JP; Laberge C; Tanguay RM
    Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I.
    Awata H; Endo F; Tanoue A; Kitano A; Nakano Y; Matsuda I
    Biochim Biophys Acta; 1994 May; 1226(2):168-72. PubMed ID: 8204664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
    Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
    Morrow G; Dreumont N; Bourrelle-Langlois M; Roy V; Tanguay RM
    Mol Genet Metab; 2019 May; 127(1):58-63. PubMed ID: 30954369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosinemia: the Quebec experience.
    Paradis K
    Clin Invest Med; 1996 Oct; 19(5):311-6. PubMed ID: 8889268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.